We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Noscapine Slows Growth and Spread of Prostate Cancer

By BiotechDaily International staff writers
Posted on 31 Mar 2010
Print article
Noscapine, a nonaddictive derivative of opium commonly used as an additive in cough medicines, has been shown to be effective in limiting the growth and spread of prostate cancer.

A cooperative effort united investigators from the Prostate Cancer Research and Education Foundation (PCREF; San Diego, CA, USA), the University of California, San Diego (UCSD; USA), and the MedInsight Research Institute (Baltimore, MD, USA). They worked with a model comprising nude mice that were injected with human prostate cancer cells.

In the study, the mice received oral noscapine or diluent (control) for 56 days, beginning seven days after inoculation with PC3 human prostate cancer cells; or noscapine for 70 days, beginning seven days before inoculation with the cancer cells.

Findings were published in the February 2010 issue of the journal Anticancer Research. They showed that pretreating the mice with noscapine before injecting them with prostate cancer cells resulted in the tumor growth rate being two-thirds smaller in the noscapine group. Furthermore, lung metastasis rates were 80% less in the mice pretreated with noscapine, and the noscapine group suffered no cancer-related weight loss – compared with significant weight loss in the non-noscapine group. Overall, pretreatment with noscapine gave anticancer benefits similar to those seen for treatment that was given after injection of cancer cells. In both cases, there were no signs of toxicity to normal cells or tissues.

"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability,” said first author Dr. Israel Barken, medical director of the PCREF. "PCREF is now seeking sponsorship for clinical data collection in postsurgery patients who are at high-risk of recurrence for their prostate cancer.”

Senior author Dr. Moshe Rogosnitzky, director of research at the MedInsight Research Institute, said, "It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today.”

Related Links:
Prostate Cancer Research and Education Foundation
University of California, San Diego
MedInsight Research Institute



Print article

Channels

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2018 Globetech Media. All rights reserved.